Navigation Links
Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors
Date:2/15/2011

further support the safety and clinical benefit of CERE-120.

For more information, see PDTrials.org or log onto Ceregene's web site (www.Ceregene.com).

About Parkinson's Disease

Parkinson's disease is a progressive movement disorder that affects a million people in the United States.  Its main symptoms, stiffness, tremors and slowed movements and gait, are caused by a loss of dopamine-containing nerve cells in the substantia nigra, which project their axons to the putamen.  Dopamine is a neurotransmitter involved in controlling movement and coordination, so Parkinson's patients exhibit a progressive inability to initiate and control physical movements.  There is currently no treatment that can reverse the degeneration of these neurons, let alone cure Parkinson's disease.

About Ceregene

Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth (neurotrophic) factors for the treatment of neurodegenerative and retinal disorders using gene delivery.  Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor (NGF) currently in a multi-center, controlled Phase 2 study for the treatment of Alzheimer's disease (in collaboration with the ADCS), and CERE-120 (AAV2-Neurturin) for Parkinson's disease.  Ceregene was launched in January 2001.  The company's investors include Alta Partners, MPM Capital, Hamilton BioVentures, Investor Growth Capital, California Technology Partners and BioSante Pharmaceuticals (Nasdaq: BPAX).


'/>"/>
SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
2. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
3. SeraCare Reports First Quarter Fiscal Year 2011 Results
4. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
5. YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
7. ERT Reports Fourth Quarter and Full Year 2010 Operating Results on March 1, 2011
8. Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
9. Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
10. Codexis Reports Fourth Quarter and Full Year 2010 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Today, TiFiber, Inc. announced ... and future company headquarters in Fort Smith, Arkansas ... that safely and effectively control dangerous microorganisms. Fort ... historic, strong support for manufacturing, but also due ... technology-based companies such as TiFiber. , In ...
(Date:12/19/2014)... iLab Solutions, the global leader in core facility ... the new Director of Institutional Implementations and Sarah Becker ... new leadership positions were created to support iLab’s mission ... continues to meet the needs of its growing customer ... been deployed at over 450 core facilities across more ...
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will grow moderately through 2023 as the aging population, ... of dental biomaterials all spur procedure volumes. Growth will ... China and India ... within reach for a larger proportion of the population. ...
(Date:12/17/2014)... New York, NY (PRWEB) December 16, 2014 ... undergone significant changes since 2013, which is why IBISWorld ... one, this industry continues to benefit from an intensified ... 2014, the proposal for new emission standards for power ... affected industry operators. According to IBISWorld Industry Analyst Sarah ...
Breaking Biology Technology:Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3
... Inc. (Nasdaq: NXXI ), the developer and ... and Diabetes Essentials(R) brands that help consumers manage blood ... chronic joint pain, today announced financial results for the ... 2009.For the quarter the Company reported total revenues of ...
... (Nasdaq: BJGP ) ("BMP Sunstone" or the "Company") ... Healthcare Services,Conference, which will be held at the Waldorf-Astoria in ... Management is currently scheduled to present at 3:30 pm ... same day. , A webcast of ...
... Genesis HealthCare, a provider of long-term care services ... today that Wendy LaBate has been promoted to Senior ... In her new position, LaBate will be responsible for ... Regional Vice Presidents of Operations and Administrators in six ...
Cached Biology Technology:Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 2Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 3Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 4Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 5Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 6Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 7BMP Sunstone to Present at UBS Global Healthcare Services Conference 2Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area 2
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... they develop, vertebrate embryos form vertebrae in a ... that this process of body segmentation is controlled ... oscillating activity of certain genes within embryonic cells. ... timing system works. A new international ...
... Ind. -- Scientists at Indiana University and international collaborators ... a single molecule, producing a more effective therapy with ... obesity and related medical conditions. , The studies were ... Standiford H. Cox Distinguished Professor of Chemistry and the ...
... A new study demonstrates the dynamic role cilia play ... brain. Cilia are tiny hair-like structures on the surfaces ... radio antennae. In developing mouse embryos, researchers were ... migrate. The cilia appear to be receiving signals needed ...
Cached Biology News:Study sheds light on genetic 'clock' in embryonic cells 2Hormone combination effective and safe for treating obesity in mice 2Cilia guide neuronal migration in developing brain 2
... Ribonuclease Inhibitor is a recombinant protein that has ... RNA in the preparation of cDNA by reverse ... vitro protein synthesis. RNA Safe Inhibitor tightly binds ... broad range of eukaryotic RNases such as RNase ...
... Natural and Recombinant RNasin Ribonuclease Inhibitors ... the inhibition of eukaryotic RNases of the ... its inhibitory effect by noncovalently binding to ... value for the binding of RNasin Ribonuclease ...
...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
Biology Products: